Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS
- PMID: 26010239
- PMCID: PMC4536115
- DOI: 10.1002/jps.24505
Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS
Abstract
This study was conducted to determine the number of drugs exhibiting flip-flop pharmacokinetics following oral (p.o.) dosing from immediate-release dosage forms and if they exhibit a common characteristic that may be predicted based on BDDCS classification. The literature was searched for drugs displaying flip-flop kinetics (i.e., absorption half-life larger than elimination half-life) in mammals in PubMed, via internet search engines and reviewing drug pharmacokinetic data. Twenty two drugs were identified as displaying flip-flop kinetics in humans (13 drugs), rat (nine drugs), monkey (three drugs), horse (two drugs), and/or rabbit (two drugs). Nineteen of the 22 drugs exhibiting flip-flop kinetics were BDDCS Classes 3 and 4. One of the three exceptions, meclofenamic acid (Class 2), was identified in the horse; however, it would not exhibit flip-flop kinetics in humans where the p.o. dosing terminal half-life is 1.4 h. The second, carvedilol, can be explained based on solubility issues, but the third sapropterin dihydrochloride (nominally Class 1) requires further consideration. The few drugs displaying p.o. flip-flop kinetics in humans are predominantly BDDCS Classes 3 and 4. New molecular entities predicted to be BDDCS Classes 3 and 4 could be liable to exhibit flip-flop kinetics when the elimination half life is short and should be suspected to be substrates for intestinal transporters.
Keywords: BDDCS; absorption; disposition; flip-flop pharmacokinetics; half-life; intestinal absorption; oral drug absorption; pharmacokinetics; transporters.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.
Figures
Similar articles
-
BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.AAPS J. 2016 Jan;18(1):251-60. doi: 10.1208/s12248-015-9845-2. Epub 2015 Nov 20. AAPS J. 2016. PMID: 26589308 Free PMC article. Review.
-
BDDCS class prediction for new molecular entities.Mol Pharm. 2012 Mar 5;9(3):570-80. doi: 10.1021/mp2004302. Epub 2012 Feb 7. Mol Pharm. 2012. PMID: 22224483 Free PMC article.
-
A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.J Pharm Sci. 2013 Sep;102(9):3136-44. doi: 10.1002/jps.23515. Epub 2013 Apr 11. J Pharm Sci. 2013. PMID: 23580377
-
Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters.J Pharm Pharm Sci. 2019;22(1):247-269. doi: 10.18433/jpps30271. J Pharm Pharm Sci. 2019. PMID: 31287788
-
Intestinal drug transporters: an overview.Adv Drug Deliv Rev. 2013 Oct;65(10):1340-56. doi: 10.1016/j.addr.2012.09.042. Epub 2012 Oct 4. Adv Drug Deliv Rev. 2013. PMID: 23041352 Review.
Cited by
-
A Systematic Review on the Clinical Pharmacokinetics of Cephalexin in Healthy and Diseased Populations.Antibiotics (Basel). 2023 Sep 3;12(9):1402. doi: 10.3390/antibiotics12091402. Antibiotics (Basel). 2023. PMID: 37760698 Free PMC article. Review.
-
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9.J Med Chem. 2025 May 8;68(9):9537-9554. doi: 10.1021/acs.jmedchem.5c00252. Epub 2025 Apr 29. J Med Chem. 2025. PMID: 40298172 Free PMC article.
-
BDDCS, the Rule of 5 and drugability.Adv Drug Deliv Rev. 2016 Jun 1;101:89-98. doi: 10.1016/j.addr.2016.05.007. Epub 2016 May 13. Adv Drug Deliv Rev. 2016. PMID: 27182629 Free PMC article. Review.
-
Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound.Sci Rep. 2018 Jan 31;8(1):1925. doi: 10.1038/s41598-018-20362-9. Sci Rep. 2018. PMID: 29386590 Free PMC article.
-
Commentary: Pharmacokinetic Theory Must Consider Published Experimental Data.Drug Metab Dispos. 2024 Aug 14;52(9):932-938. doi: 10.1124/dmd.124.001735. Drug Metab Dispos. 2024. PMID: 38942444 Free PMC article.
References
-
- Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420. - PubMed
-
- Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23. - PubMed
-
- Han N, Yun HY, Kim IW, Oh YJ, Kim YS, Oh JM. Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014;70(10):1211–1219. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical